Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer

Basit Öğe Kaydı
dc.authoridKartal Yandim, Melis/0000-0003-0573-4276
dc.authoridBaran, Yusuf/0000-0002-1056-4673
dc.authorwosidApohan, Elif/AAA-5142-2021
dc.authorwosidKartal Yandim, Melis/O-1535-2015
dc.contributor.authorYandim, Melis Kartal
dc.contributor.authorApohan, Elif
dc.contributor.authorBaran, Yusuf
dc.date.accessioned2024-08-04T20:37:23Z
dc.date.available2024-08-04T20:37:23Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractSphingolipids including ceramides and its derivatives such as ceramide-1-phosphate, glucosylceramide (GlcCer), and sphingosine-1-phosphate are essential structural components of cell membranes. They now recognized as novel bioeffector molecules which control various aspects of cell growth, proliferation, apoptosis, and drug resistance. Ceramide, the central molecule of sphingolipid metabolism, generally mediates anti-proliferative responses such as inhibition of cell growth, induction of apoptosis, and/or modulation of senescence. There are two major classes of sphingolipids. One of them is glycosphingolipids which are synthesized from the hydrophobic molecule, ceramide. GlcCer, generated by glucosylceramide synthase (GCS) that transfers the glucose from UDP-glucose to ceramide, is an important glycosphingolipid metabolic intermediate. GCS regulates the balance between apoptotic ceramide and antiapoptotic GlcCer. Downregulation or inhibition of GCS results in increased apoptosis and decreased drug resistance. The mechanism underlying the drug resistance which develops with increased glucosylceramide expression is associated with P-glycoprotein. In various types of cancers, overexpression of GCS has been observed which renders GCS a good target for the treatment of cancer. This review summarizes our current knowledge on the structure and functions of glucosylceramide synthase and glucosylceramide and on the roles of glucosylceramide synthase in cancer therapy and drug resistance.en_US
dc.identifier.doi10.1007/s00280-012-1984-x
dc.identifier.endpage20en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue1en_US
dc.identifier.pmid23073611en_US
dc.identifier.scopus2-s2.0-84872356927en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage13en_US
dc.identifier.urihttps://doi.org/10.1007/s00280-012-1984-x
dc.identifier.urihttps://hdl.handle.net/11616/95924
dc.identifier.volume71en_US
dc.identifier.wosWOS:000313004900002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGlucosylceramide synthaseen_US
dc.subjectCancer therapyen_US
dc.subjectGlucosylceramideen_US
dc.subjectDrug resistanceen_US
dc.subjectCeramideen_US
dc.subjectSphingolipiden_US
dc.titleTherapeutic potential of targeting ceramide/glucosylceramide pathway in canceren_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu